by | Jun 19, 2024 | Uncategorized
Source: CureToday articles One expert explains why double autologous stem cell transplantation is a viable alternative to back-to-back transplant in high-risk multiple myeloma. Read More
by | Jun 19, 2024 | Uncategorized
Source: CureToday articles One expert explains why double autologous stem cell transplantation is a viable alternative to back-to-back transplant in high-risk multiple myeloma. Read More
by | Jun 19, 2024 | Uncategorized
Source: CureToday articles One expert explains why double autologous stem cell transplantation is a viable alternative to back-to-back transplant in high-risk multiple myeloma. Read More
by | Jun 19, 2024 | Uncategorized
EJHaem. 2024 Apr 30;5(3):485-493. doi: 10.1002/jha2.907. eCollection 2024 Jun. ABSTRACT Belantamab mafodotin is the first-in-class antibody-drug conjugates targeting B-cell maturation antigen to have demonstrated effectiveness in triple-class refractory multiple...
by | Jun 18, 2024 | Uncategorized
CHICAGO — In this video, Henry Chi Hang Fung, MD, FACP, FRCPE, spoke with Healio about a study in older patients with relapsed/refractory multiple myeloma.The study was presented at ASCO Annual Meeting and investigated an oral two-drug regimen for frail patients with...
by | Jun 17, 2024 | Uncategorized
CHICAGO — Henry Chi Hang Fung, MD, FACP, FRCPE, spoke with Healio about findings from DREAMM-7 and DREAMM-8— both presented at ASCO Annual Meeting.A previous study assessing belantamab mafodotin monotherapy for the treatment of relapsed refractory multiple myeloma did...